Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells

Area of Science:

• Immunology
• Cancer Research
• Molecular Biology

Background:

• Cancer/testis antigens like SSX2 play a role in tumor immunity.
• The SSX2-derived peptide SSX2(103-111) is presented by HLA-A*0201 molecules on cancer cells.
• Melanoma cell lines SK-Mel-37 and Me275 differ in their ability to stimulate SSX2(103-111)-specific T-cells.

Purpose of the Study:

• To visualize the presentation of the SSX2(103-111) peptide in the context of HLA-A*0201 on melanoma cells.
• To correlate SSX2(103-111) peptide presentation with T-cell stimulation.
• To evaluate the utility of MHC-peptide specific antibodies in analyzing antigenic peptide presentation.

Main Methods:

• Development of SSX2(103-111)/HLA-A*0201 specific Fab-antibodies from a phage library.
• Visualization of peptide-MHC complex presentation on melanoma cell lines SK-Mel-37 and Me275 using fluorescence microscopy.
• Assessment of T-cell reactivity against melanoma cells using SSX2(103-111)-specific T-cell clones.

Main Results:

• Fab-antibodies successfully visualized SSX2(103-111)/HLA-A*0201 complexes on the cell surface.
• High presentation of SSX2(103-111) was observed on SK-Mel-37 cells, while Me275 cells showed minimal presentation (<1%).
• Peptide presentation, not SSX2 protein expression, correlated with the stimulation of SSX2(103-111)-specific T-cells.

Conclusions:

• MHC-peptide specific antibodies are effective tools for studying peptide presentation.
• The level of SSX2(103-111) presentation on melanoma cells directly influences T-cell immune response.
• This methodology aids in defining immunodominant epitopes and understanding tumor antigen presentation.